Solasia Pharma K.K. (4597.T)
JPY 42.0
(2.44%)
JPY 42.0
(2.44%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -359 Million | -2.07 Billion | -2.47 Billion | -2.78 Billion | -828 Million | -2.32 Billion |
| Net Income | -1.11 Billion | -2.49 Billion | -2.44 Billion | -4.15 Billion | -1.79 Billion | -2.44 Billion |
| Depreciation & Amortization | 500 Million | 534 Million | 495 Million | 496 Million | 475 Million | 153 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 307 Million | -525 Million | -571 Million | 64 Million | 451 Million | 15 Million |
| Other non-cash items | -54 Million | 409 Million | 45 Million | 810 Million | 43 Million | -46 Million |
| Investing Cash Flow | 2 Million | -418 Million | -164 Million | -171 Million | -735 Million | -256 Million |
| Investments in PPE | - | -403 Million | -163 Million | -171 Million | -732 Million | -257 Million |
| Acquisitions | - | -14 Million | - | - | - | - |
| Investment purchases | - | -14 Million | - | - | - | - |
| Sales/Maturities of investments | - | 14 Million | - | - | - | - |
| Other Investing Activities | - | -1 Million | -1 Million | -161 Million | -3 Million | 1 Million |
| Financing Cash Flow | 275 Million | 2.57 Billion | 361 Million | 1.82 Billion | 1.64 Billion | 3.26 Billion |
| Debt repayment | - | -500 Million | -1 Billion | -1.5 Billion | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -3 Million | - | - | -22 Million | -48 Million |
| Common Stock Issuance | 318 Million | 2.61 Billion | 1.4 Billion | 861 Million | 1.7 Billion | 3.3 Billion |
| Other Financing Activities | -43 Million | 459 Million | -42 Million | 2.46 Billion | -41 Million | -1 Million |
| Accounts receivables | 540 Million | -446 Million | 51 Million | -160 Million | 182 Million | -174 Million |
| Accounts payables | -118 Million | -65 Million | -626 Million | 225 Million | 151 Million | 217 Million |
| Inventory | -108 Million | -14 Million | 4 Million | -1 Million | 118 Million | -28 Million |
| Other working capital | -7 Million | -13 Million | 47 Million | -18 Million | 7 Million | 43 Million |
| Cash at beginning of period | 803 Million | 714 Million | 2.96 Billion | 4.11 Billion | 4.04 Billion | 3.37 Billion |
| Cash at end of period | 728 Million | 803 Million | 714 Million | 2.96 Billion | 4.11 Billion | 4.04 Billion |
| Capital Expenditure | - | -403 Million | -163 Million | -171 Million | -732 Million | -257 Million |
| Effect of forex changes on cash | 7 Million | 10 Million | 25 Million | -20 Million | -6 Million | -4 Million |
| Net cash flow / Change in cash | -75 Million | 89 Million | -2.25 Billion | -1.15 Billion | 70 Million | 676 Million |
| Free Cash Flow | -359 Million | -2.47 Billion | -2.63 Billion | -2.96 Billion | -1.56 Billion | -2.58 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -300 Million | -310 Million | -1.11 Billion | -344 Million | -334 Million | -203 Million |
| Depreciation & Amortization | 34 Million | 93 Million | 500 Million | 122 Million | 126 Million | 126 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -24 Million | 51 Million | 307 Million | 134 Million | 266 Million | -429 Million |
| Other non-cash items | 92 Million | 136 Million | -54 Million | -9 Million | 10 Million | -47 Million |
| Investing Cash Flow | - | - | 2 Million | - | -1 Million | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -68 Million | 743 Million | 275 Million | 302 Million | -4 Million | -11 Million |
| Debt repayment | -500 Million | -500 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 443 Million | 248 Million | 318 Million | 311 Million | 6 Million | 1 Million |
| Other Financing Activities | -2 Million | 3 Million | -43 Million | -9 Million | -10 Million | -12 Million |
| Accounts receivables | -29 Million | 40 Million | 540 Million | 138 Million | 340 Million | -270 Million |
| Accounts payables | -20 Million | 32 Million | -118 Million | 5 Million | -71 Million | -97 Million |
| Inventory | 5 Million | -20 Million | -108 Million | -2 Million | -3 Million | -62 Million |
| Other working capital | 20 Million | -1 Million | -7 Million | -7 Million | 1 Million | -9 Million |
| Cash at beginning of period | 1.31 Billion | 728 Million | 803 Million | 520 Million | 453 Million | 1.01 Billion |
| Cash at end of period | 942 Million | 1.31 Billion | 728 Million | 728 Million | 520 Million | 453 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | 2 Million | 11 Million | 7 Million | - | 4 Million | 1 Million |
| Net cash flow / Change in cash | -377 Million | 591 Million | -75 Million | 208 Million | 67 Million | -563 Million |
| Free Cash Flow | -310 Million | -164 Million | -359 Million | -97 Million | 68 Million | -553 Million |
IDEXF
TURSG
NIKHILAD
NORBTEAEXP
ARMX
MPG